Clinical Trials
5 trialsNCT02450903 2021-03-30
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Phase 2 Completed
NCT02276027 2020-12-16
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT02336451 2020-04-21
Ascend-7
Novartis
Phase 2 Completed
NCT01685138 2019-03-26
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT01685060 2017-06-19
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Novartis
Phase 2 Completed